{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397292,"version":"4.6.1"},"reference-count":85,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Psoriasis is a systemic immune-mediated chronic inflammatory skin disease; its systemic manifestations and periodic recurrence negatively affect a patient\u2019s quality of life. Inflammatory cytokines are known to have an important role in the onset and progression of psoriasis, however, data on the association between circulating inflammatory cytokines and psoriasis risk is inconclusive. Here, we explore the relevance of circulating proinflammatory factors to the pathogenesis of psoriasis using a meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To explore the association between circulating levels of inflammatory factors and psoriasis to elucidate the mechanisms underlying psoriasis and improve clinical diagnosis and treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We systematically retrieved articles published in PubMed, EMBASE, the Cochrane Library and the Web of Science from the establishment of each database to January 2023. The standard mean difference (SMD) in cytokine levels of individuals with psoriasis and healthy controls was used to check for correlations between circulating inflammatory factor levels and psoriasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Fifty-seven studies, with data from 2838 patients, were retrieved and included in the meta-analysis. Eleven inflammatory factors were studied (circulating interleukin-2 (IL-2), IL-4, IL-12, IL-17, IL-18, IL-22, IL-23, IL-35, IL-36, transforming growth factor-beta (TGF-\u03b2) and gamma-interferon (IFN-\u03b3)). Of these, IL-2 [SMD = 1.29 (95% CI: 0.61\u20131.97; P &lt;0.001)], IL-17 [SMD = 0.71 (95% CI: 0.12\u20131.30; P = 0.018)], IL-18 [SMD = 1.27 (95% CI: 0.64\u20131.90; P &lt;0.001)], and IFN-\u03b3 [SMD = 1.90 (95% CI: 1.27\u20132.52; P &lt;0.001)] levels had significant correlations with psoriasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Increased serum concentrations of the circulating inflammatory cytokines IL-2, IL-17, IL-18 and IFN-\u03b3 were significantly correlated with psoriasis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0293327","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:25:35Z","timestamp":1698341135000},"page":"e0293327","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"given":"Xiao-Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Hu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-9873","authenticated-orcid":true,"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"1","key":"pone.0293327.ref001","first-page":"97","article-title":"Current Developments in the Immunology of Psoriasis","volume":"93","author":"F Gr\u00e4n","year":"2020","journal-title":"The Yale Journal of Biology and Medicine"},{"issue":"6","key":"pone.0293327.ref002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"F. Yamazaki","year":"2021","journal-title":"The Journal of dermatology"},{"key":"pone.0293327.ref003","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.ceca.2021.102429","article-title":"Cimifugin relieves pruritus in psoriasis by inhibiting TRPV4","volume":"97","author":"J Yan","year":"2021","journal-title":"Cell Calcium"},{"issue":"1","key":"pone.0293327.ref004","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"JE Greb","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"6","key":"pone.0293327.ref005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis Pathogenesis and Treatment","volume":"20","author":"A Rendon","year":"2019","journal-title":"International journal of molecular sciences"},{"issue":"20","key":"pone.0293327.ref006","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New Treatment Addressing the Pathogenesis of Psoriasis","volume":"21","author":"M Tokuyama","year":"2020","journal-title":"International journal of molecular sciences"},{"issue":"4","key":"pone.0293327.ref007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"L Wang","year":"2015","journal-title":"Journal of internal medicine"},{"issue":"3","key":"pone.0293327.ref008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"A Blauvelt","year":"2018","journal-title":"Clinical reviews in allergy & immunology"},{"issue":"8","key":"pone.0293327.ref009","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.3390\/ijms23084457","article-title":"Psoriasis and Systemic Inflammatory Disorders","volume":"23","author":"T Tashiro","year":"2022","journal-title":"International journal of molecular sciences"},{"issue":"2","key":"pone.0293327.ref010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"X Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"pone.0293327.ref011","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond","volume":"9","author":"NC Brembilla","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"9","key":"pone.0293327.ref012","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.7150\/thno.31144","article-title":"In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine","volume":"9","author":"M Xu","year":"2019","journal-title":"Theranostics"},{"issue":"18","key":"pone.0293327.ref013","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk Factors for the Development of Psoriasis","volume":"20","author":"K Kamiya","year":"2019","journal-title":"International journal of molecular sciences"},{"key":"pone.0293327.ref014","doi-asserted-by":"crossref","first-page":"2787954","DOI":"10.1155\/2022\/2787954","article-title":"Profiling Serum Cytokines and Anticytokine Antibodies in Psoriasis Patients","volume":"2022","author":"D Hong","year":"2022","journal-title":"Journal of immunology research"},{"issue":"7","key":"pone.0293327.ref015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors","volume":"68","author":"C Cataldi","year":"2019","journal-title":"Inflammation Research"},{"key":"pone.0293327.ref016","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2021.622306","article-title":"The Role of Natural Killer Cells in Autoimmune Diseases","volume":"12","author":"U C Kucuksezer","year":"2021","journal-title":"Frontiers in immunology"},{"issue":"3","key":"pone.0293327.ref017","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/1744666X.2017.1279054","article-title":"The role of IL-4 in psoriasis","volume":"13","author":"M Hahn","year":"2017","journal-title":"Expert review of clinical immunology"},{"issue":"23","key":"pone.0293327.ref018","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.3390\/ijms222312793","article-title":"The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications","volume":"22","author":"R Singh","year":"2021","journal-title":"Int J Mol Sci y"},{"issue":"7","key":"pone.0293327.ref019","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"MW Teng","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"pone.0293327.ref020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"J M Fletcher","year":"2020","journal-title":"Clinical and experimental immunology"},{"issue":"1","key":"pone.0293327.ref021","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"J Ruiz D Morales","year":"2020","journal-title":"Autoimmunity reviews"},{"key":"pone.0293327.ref022","doi-asserted-by":"crossref","first-page":"955369","DOI":"10.3389\/fimmu.2023.955369","article-title":"Interleukin-18 and IL-18BP in inflammatory dermatological diseases","volume":"14","author":"X WAng","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"6","key":"pone.0293327.ref023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.smim.2013.10.014","article-title":"Interleukin-18, more than a Th1 cytokine","volume":"25","author":"D Novick","year":"2013","journal-title":"Seminars in Immunology"},{"key":"pone.0293327.ref024","doi-asserted-by":"crossref","first-page":"688066","DOI":"10.3389\/fimmu.2021.688066","article-title":"Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases","volume":"12","author":"Q Jiang","year":"2021","journal-title":"Frontiers in immunology"},{"key":"pone.0293327.ref025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"M A Lowes","year":"2014","journal-title":"Annual review of immunology"},{"key":"pone.0293327.ref026","doi-asserted-by":"crossref","first-page":"788940","DOI":"10.3389\/fimmu.2021.788940","article-title":"The Role of Helper T Cells in Psoriasis","volume":"12","author":"P Hu","year":"2021","journal-title":"Frontiers in immunology"},{"issue":"1","key":"pone.0293327.ref027","first-page":"177","article-title":"Targeted Immunotherapy for Autoimmune Disease","volume":"22","author":"S M Jung","year":"2022","journal-title":"Immune Network"},{"issue":"5","key":"pone.0293327.ref028","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jbspin.2013.04.014","article-title":"Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38","volume":"80","author":"G Clavel","year":"2013","journal-title":"Joint bone spine"},{"key":"pone.0293327.ref029","first-page":"13428","article-title":"IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells","volume":"20","author":"Y Wang","year":"2017","journal-title":"Journal of cellular and molecular medicine"},{"issue":"2","key":"pone.0293327.ref030","doi-asserted-by":"crossref","first-page":"13428","DOI":"10.1172\/JCI144336","article-title":"IL-36 in chronic inflammation and fibrosis\u2014bridging the gap?","volume":"131","author":"M Elias","year":"2021","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"pone.0293327.ref031","first-page":"155","article-title":"Transcriptional regulation on effector T cells in the pathogenesis of psoriasis","volume":"28","author":"Y Qu","year":"2023","journal-title":"European Journal of Medical Research"},{"key":"pone.0293327.ref032","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"MJ Page","year":"2021","journal-title":"International journal of surgery"},{"key":"pone.0293327.ref033","unstructured":"National Heart L, and Blood Institute. Study Quality Assessment Tools."},{"issue":"2","key":"pone.0293327.ref034","first-page":"230","article-title":"A study of inflammatory markers and their correlation with PASI score in psoriasis\u2013A case control study","volume":"42","author":"NB Mannangi","year":"2022","journal-title":"Biomedicine (India)"},{"issue":"4","key":"pone.0293327.ref035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijdvl.IJDVL_471_17","article-title":"Is there a correlation of serum and tissue T helper-1 and-2 cytokine profiles with psoriasis activity and severity? A cross-sectional study","volume":"84","author":"S Khandpur","year":"2018","journal-title":"Indian journal of dermatology, venereology and leprology"},{"issue":"6","key":"pone.0293327.ref036","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2230.2009.03704.x","article-title":"Serum cytokines and growth factor levels in Japanese patients with psoriasis","volume":"35","author":"H Takahashi","year":"2010","journal-title":"Clinical and experimental dermatology"},{"issue":"1","key":"pone.0293327.ref037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000339866","article-title":"Comparative study of systemic inflammatory responses in psoriasis vulgaris and mild to moderate allergic contact dermatitis","volume":"225","author":"S Kaur","year":"2012","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"1","key":"pone.0293327.ref038","first-page":"40","article-title":"Serum cytokine levels in psoriasis vulgaris","volume":"58","author":"NY Barnawi","year":"2001","journal-title":"British journal of biomedical science"},{"issue":"4","key":"pone.0293327.ref039","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2133.2012.11038.x","article-title":"A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis","volume":"167","author":"YB Choe","year":"2012","journal-title":"The British Journal of Dermatology"},{"issue":"1","key":"pone.0293327.ref040","first-page":"46","article-title":"Research on different expressions of peripheral blood Th1\/Th2 cells in psoriasis patients of blood heat syndrome and of blood stasis syndrome","volume":"34","author":"J Chen","year":"2014","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"issue":"4","key":"pone.0293327.ref041","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12291-011-0156-9","article-title":"Serum cytokine profile in psoriasis-A case-control study in a tertiary care hospital from Northern India","volume":"26","author":"B Verghese","year":"2011","journal-title":"Indian Journal of Clinical Biochemistry"},{"issue":"6","key":"pone.0293327.ref042","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1155\/2013\/856056","article-title":"Serum levels of selected Th17 and Th22 cytokines in psoriatic patients","volume":"35","author":"A Michalak-Stoma","year":"2013","journal-title":"Disease markers"},{"key":"pone.0293327.ref043","doi-asserted-by":"crossref","first-page":"467541","DOI":"10.1155\/2014\/467541","article-title":"Serum levels of TNF-\u03b1, IL-12\/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity","volume":"2014","author":"A Kyriakou","year":"2014","journal-title":"Journal of immunology research"},{"issue":"5","key":"pone.0293327.ref044","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"O Arican","year":"2005","journal-title":"Mediators of inflammation"},{"key":"pone.0293327.ref045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cyto.2016.06.020","article-title":"Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report","volume":"85","author":"MJ Brito-Luna","year":"2016","journal-title":"Cytokine"},{"issue":"11","key":"pone.0293327.ref046","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1111\/jocd.15262","article-title":"Pro-inflammatory versus anti-inflammatory cytokines in psoriatic patients (case-control study)","volume":"21","author":"AM Elbana","year":"2022","journal-title":"Journal of cosmetic dermatology"},{"issue":"2","key":"pone.0293327.ref047","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11655-014-1792-0","article-title":"Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes","volume":"21","author":"ML Xuan","year":"2015","journal-title":"Chinese journal of integrative medicine"},{"issue":"6","key":"pone.0293327.ref048","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475415584503","article-title":"IL-17A, IL-22, and IL-23 as markers of psoriasis activity: A cross-sectional, hospital-based study","volume":"19","author":"C Fotiadou","year":"2015","journal-title":"Journal of cutaneous medicine and surgery"},{"issue":"7","key":"pone.0293327.ref049","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ced.12845","article-title":"Circulating T-helper 17 cells and associated cytokines in psoriasis","volume":"41","author":"S Chhabra","year":"2016","journal-title":"Clinical and experimental dermatology"},{"issue":"10","key":"pone.0293327.ref050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00403-021-02308-w","article-title":"Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk","volume":"314","author":"B Ak\u015fan","year":"2022","journal-title":"Archives of dermatological research"},{"issue":"11","key":"pone.0293327.ref051","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1111\/jocd.15299","article-title":"Serum immunoglobulin E and Interleukin-17 levels in patients with chronic plaque psoriasis: A case-control study","volume":"21","author":"AA Nassar","year":"2022","journal-title":"Journal of cosmetic dermatology"},{"issue":"8","key":"pone.0293327.ref052","doi-asserted-by":"crossref","first-page":"e0201589","DOI":"10.1371\/journal.pone.0201589","article-title":"Serum concentrations of interleukin 18 and 25-hydroxyvitamin D3 correlate with depression severity in men with psoriasis","volume":"13","author":"D Pietrzak","year":"2018","journal-title":"PloS one"},{"issue":"4","key":"pone.0293327.ref053","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00015550310016508","article-title":"Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score","volume":"83","author":"A Pietrzak","year":"2003","journal-title":"Acta dermato-venereologica"},{"issue":"1","key":"pone.0293327.ref054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1468-3083.2003.00647.x","article-title":"Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations","volume":"17","author":"S Gangemi","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"4","key":"pone.0293327.ref055","first-page":"317","article-title":"Serum levels of IL-10 and IL-22 cytokines in patients with psoriasis","volume":"13","author":"MR Sobhan","year":"2016","journal-title":"Iranian Journal of Immunology"},{"issue":"2","key":"pone.0293327.ref056","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/01.EWX.0000511083.73976.6f","article-title":"Relationship between microRNA-369-3p, SIRT1, and IL-22 in psoriasis vulgaris","volume":"14","author":"ERM Hofny","year":"2017","journal-title":"Journal of the Egyptian Women\u2019s Dermatologic Society"},{"key":"pone.0293327.ref057","doi-asserted-by":"crossref","first-page":"467541","DOI":"10.1155\/2014\/467541","article-title":"Serum levels of TNF-, IL-12\/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity","volume":"2014","author":"A Kyriakou","year":"2014","journal-title":"Journal of immunology research"},{"issue":"5","key":"pone.0293327.ref058","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3906\/sag-1904-48","article-title":"Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasis","volume":"49","author":"B Filiz","year":"2019","journal-title":"Turkish journal of medical sciences"},{"issue":"6","key":"pone.0293327.ref059","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/09546634.2019.1689226","article-title":"Correlation analysis between IL-35, IL-36\u03b3, CCL27 and psoriasis vulgaris","volume":"32","author":"J Chen","year":"2021","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"pone.0293327.ref060","first-page":"179","article-title":"Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris","volume":"17","author":"M Sehat","year":"2018","journal-title":"Iranian journal of allergy, asthma, and immunology"},{"issue":"3","key":"pone.0293327.ref061","first-page":"163","article-title":"Serum interferon-gamma is a psoriasis severity and prognostic marker","volume":"84","author":"MA Abdallah","year":"2009","journal-title":"Cutis"},{"issue":"6","key":"pone.0293327.ref062","first-page":"8301","article-title":"Evaluation of Serum Interferon Gamma in Patients with Vitiligo and Psoriasis versus Control Group","volume":"20","author":"MYMA Mawla","year":"2022","journal-title":"The Egyptian Journal of Hospital Medicine"},{"key":"pone.0293327.ref063","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/CCID.S281585","article-title":"Tgf-\u03b21 gene polymorphism and its correlation with serum level of tgf-\u03b21 in psoriasis vulgaris among iraqi people","volume":"13","author":"BT Ahmed","year":"2020","journal-title":"Clinical, cosmetic and investigational dermatology"},{"issue":"6","key":"pone.0293327.ref064","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jcla.21717","article-title":"Serum vascular endothelial growth factor, transforming growth factor \u03b21, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity","volume":"28","author":"AR Meki","year":"2014","journal-title":"Journal of clinical laboratory analysis"},{"issue":"4","key":"pone.0293327.ref065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1468-3083.2008.03064.x","article-title":"Serum and tissue expression of transforming growth factor beta 1 in psoriasis","volume":"23","author":"H Zaher","year":"2009","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"9270","key":"pone.0293327.ref066","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system","volume":"357","author":"J Parkin","year":"2001","journal-title":"Lancet (London, England)"},{"issue":"4","key":"pone.0293327.ref067","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1091581815584918","article-title":"Cytokines: The Good, the Bad, and the Deadly","volume":"34","author":"T Ramani","year":"2015","journal-title":"Int J Toxicol"},{"issue":"1","key":"pone.0293327.ref068","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"DM Schwartz","year":"2016","journal-title":"Nature reviews Rheumatology"},{"issue":"11","key":"pone.0293327.ref069","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Y Jamilloux","year":"2019","journal-title":"Autoimmunity reviews"},{"issue":"2","key":"pone.0293327.ref070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/JLB.5MR0120-218RRR","article-title":"The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases","volume":"108","author":"AL Chetaille Nezondet","year":"2020","journal-title":"Journal of leukocyte biology"},{"issue":"1","key":"pone.0293327.ref071","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/ceji.2018.74873","article-title":"Association of the TNF-alpha, IL-2, and IL-2RB gene variants with susceptibility to psoriasis in a Turkish cohort","volume":"43","author":"A Gulel","year":"2018","journal-title":"Cent Eur J Immunol"},{"issue":"1","key":"pone.0293327.ref072","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"ME Raeber","year":"2018","journal-title":"Immunol Rev"},{"key":"pone.0293327.ref073","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","article-title":"Natural and modified IL-2 for the treatment of cancer and autoimmune diseases","volume":"206","author":"M Mizui","year":"2019","journal-title":"Clinical immunology (Orlando, Fla)"},{"issue":"2","key":"pone.0293327.ref074","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"M Rosenzwajg","year":"2019","journal-title":"Annals of the rheumatic diseases"},{"key":"pone.0293327.ref075","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320916014","article-title":"The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2","volume":"11","author":"J Wang","year":"2020","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"1","key":"pone.0293327.ref076","doi-asserted-by":"crossref","first-page":"e0278390","DOI":"10.1371\/journal.pone.0278390","article-title":"Sustaining the T-cell activity in xenografted psoriasis skin","volume":"18","author":"PKF Christensen","year":"2023","journal-title":"PloS one"},{"issue":"6","key":"pone.0293327.ref077","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"JE Hawkes","year":"2018","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"key":"pone.0293327.ref078","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"CA Dinarello","year":"2013","journal-title":"Frontiers in immunology"},{"issue":"2","key":"pone.0293327.ref079","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/eji.200636420","article-title":"IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes","volume":"37","author":"N Kanda","year":"2007","journal-title":"European journal of immunology"},{"key":"pone.0293327.ref080","doi-asserted-by":"crossref","first-page":"919973","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment","volume":"13","author":"SA Ihim","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"6","key":"pone.0293327.ref081","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jaci.2020.12.657","article-title":"Cross-talk between IFN-gamma and TWEAK through miR-149 amplifies skin inflammation in psoriasis","volume":"147","author":"A Srivastava","year":"2021","journal-title":"The Journal of allergy and clinical immunology"},{"key":"pone.0293327.ref082","doi-asserted-by":"crossref","first-page":"657768","DOI":"10.3389\/fimmu.2021.657768","article-title":"Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy","volume":"12","author":"C D Moorman","year":"2021","journal-title":"Frontiers in immunology"},{"key":"pone.0293327.ref083","first-page":"1","article-title":"Serum Levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity","volume":"201561","author":"Ozer Arican","year":"2005","journal-title":"Mediators of Inflammation"},{"issue":"1","key":"pone.0293327.ref084","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cyto.a.22348","article-title":"T helper cells plasticity in inflammation","volume":"85","author":"L Cosmi","year":"2014","journal-title":"Cytometry Part A"},{"issue":"2022","key":"pone.0293327.ref085","first-page":"1","article-title":"From IL-17 to IFN-\u03b3 in inflammatory skin disorders: Is transdifferentiation a potential treatment target?","volume":"13","author":"A Belpaire","year":"2022","journal-title":"Frontiers in immunology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:26:40Z","timestamp":1698341200000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293327"}},"subtitle":[],"editor":[{"given":"Engin","family":"Berber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":85,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293327","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}